Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + BCG vs BCG in High-Risk NMIBC (BCG-TIME)
NCT07064863Phase 2Not yet recruiting
- Sponsor
- Queen's University
- Start
- Aug 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine in non-muscle-invasive bladder cancer (NMIBC), sponsored by Queen's University. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
gemcitabine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07064863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07064863.